Summary:
- Laekna Therapeutics, a clinical-stage biopharmaceutical company, has announced the Investigational New Drug (IND) approval of LAE120, a novel USP1 inhibitor, by the U.S. Food and Drug Administration (FDA).
- LAE120 is a first-in-class USP1 inhibitor that is being developed for the treatment of various solid tumors, including ovarian, breast, and bladder cancers.
- The IND approval allows Laekna to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of LAE120 in patients with advanced solid tumors.